Up to your usual tricks, Harvett?
Rasul: The majority of patients were previously treated with abiraterone/enzalutamide (69%) and docetaxel/cabazitaxel (67%)
LuPIN: All patients had received and failed two prior lines of therapy (chemotherapy and androgen signalling inhibitors) and most patients (29/32) had failed a third line of therapy (another chemotherapy) prior to entering the trial.
These trials have wildly different patient criteria. You should include a disclaimer with your posts, to acknowledge your unbalanced views.
Up to your usual tricks, Harvett? Rasul: The majority of...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 14.0¢ | 11.0¢ | $559.0K | 4.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6612 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 99714 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |